Holly E. Hartman, MS; Yilun Sun, PhD; Theresa P. Devasia, MS; et al.
free access
JAMA Oncol. 2020;6(12):1881-1889. doi:10.1001/jamaoncol.2020.5403
This decision analytical model uses a web-based application and data from the Surveillance, Epidemiology, and End Results program to quantitatively integrate mortality estimates and to examine the impact of cancer treatment delay among adults with cancer during the coronavirus disease 2019 pandemic.
Nicholas J. Short, MD; Shouhao Zhou, PhD; Chenqi Fu, MS; et al.
free access
has audio
JAMA Oncol. 2020;6(12):1890-1899. doi:10.1001/jamaoncol.2020.4600
This meta-analysis examines the use of measurable residual disease as an end point in studies to assess survival outcomes in patients with acute myeloid leukemia.
-
Podcast:
Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia
-
Invited Commentary
Minimal Residual Disease in Acute Myeloid Leukemia
Deepa Jeyakumar, MD; Susan O鈥橞rien, MD
JAMA Oncol
Kerstin A. Eitz, PhD; Simon S. Lo, MD; Hany Soliman, MD; et al.
free access
JAMA Oncol. 2020;6(12):1901-1909. doi:10.1001/jamaoncol.2020.4630
This cohort study looks at outcomes and prognostic factors associated with overall survival and local control after hypofractionated stereotactic radiotherapy to the resection cavity of patients with brain metastases.
Robert T. Dess, MD; Krithika Suresh, PhD; Michael J. Zelefsky, MD; et al.
free access
JAMA Oncol. 2020;6(12):1912-1920. doi:10.1001/jamaoncol.2020.4922
This cohort study develops and validates a pretreatment clinical prognostic stage group system for patients with nonmetastatic prostate cancer.
-
Invited Commentary
Improving Pretreatment Risk Prognostication in Localized Prostate Cancer
Yaw A. Nyame, MD, MS, MBA; Willie Underwood III, MD, MSc, MPH
JAMA Oncol
Isabelle Ray-Coquard, MD; Philipp Harter, MD; Domenica Lorusso, MD; et al.
free access
JAMA Oncol. 2020;6(12):1923-1930. doi:10.1001/jamaoncol.2020.4574
This randomized clinical trial examines the efficacy of weekly paclitaxel with or without bevacizumab as treatment for relapsed sex cord-stromal tumors and whether the addition of bevacizumab to weekly paclitaxel improves 6-month progression-free rates.
Hidetoshi Hayashi, MD, PhD; Yuichi Takiguchi, MD, PhD; Hironobu Minami, MD, D Med Sci; et al.
free access
JAMA Oncol. 2020;6(12):1931-1938. doi:10.1001/jamaoncol.2020.4643
This clinical trial assesses the clinical use of site-specific treatment, including molecularly targeted therapy based on next-generation sequencing results, for Japanese patients with cancer of unknown primary site.
Timothy F. Cloughesy, MD; Kevin Petrecca, MD; Tobias Walbert, MD; et al.
free access
JAMA Oncol. 2020;6(12):1939-1946. doi:10.1001/jamaoncol.2020.3161
This randomized clinical trial compares overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) vs standard of care.
Christopher R. Manz, MD; Ravi B. Parikh, MD, MPP; Dylan S. Small, PhD; et al.
open access
online only
JAMA Oncol. 2020;6(12):e204759. doi:10.1001/jamaoncol.2020.4759
This stepped-wedge cluster randomized clinical trial assesses the effect of a clinician-directed intervention combining machine learning mortality predictions with behavioral nudges vs usual care on motivating serious illness conversations between clinicians and patients with cancer.
Mohamad Bassam Sonbol, MD; Irbaz Bin Riaz, MD, MS; Syed Arsalan Ahmed Naqvi, MBBS; et al.
free access
online only
JAMA Oncol. 2020;6(12):e204930. doi:10.1001/jamaoncol.2020.4930
This systematic review with meta-analysis compares the effectiveness of different vascular endothelial growth factor inhibitors, checkpoint inhibitors, or their combinations in patients with advanced hepatocellular carcinoma in the first-line or refractory settings.